These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 32097925)

  • 1. Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Tada T; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Toyoda H; Ohama H; Tsutsui A; Itokawa N; Hayama K; Arai T; Imai M; Nakamura S; Michitaka K; Hiasa Y; Kudo M;
    Oncology; 2020; 98(5):295-302. PubMed ID: 32097925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.
    Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K; Kudo M;
    Cancer Med; 2019 Jul; 8(8):3719-3728. PubMed ID: 31127698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Tanaka H; Tamai T; Koizumi Y; Hiasa Y; Michitaka K; Kudo M; ;
    Oncology; 2019; 97(5):277-285. PubMed ID: 31307035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib.
    Tada T; Kumada T; Hiraoka A; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Takaaki T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
    Sci Rep; 2021 Jul; 11(1):14474. PubMed ID: 34262065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K;
    Oncology; 2019; 97(6):334-340. PubMed ID: 31466068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined prognostic nutritional index and albumin-bilirubin grade to predict the postoperative prognosis of HBV-associated hepatocellular carcinoma patients.
    Liang X; Liangliang X; Peng W; Tao Y; Jinfu Z; Ming Z; Mingqing X
    Sci Rep; 2021 Jul; 11(1):14624. PubMed ID: 34272447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome.
    Fuchigami A; Imai Y; Uchida Y; Uchiya H; Fujii Y; Nakazawa M; Ando S; Sugawara K; Nakayama N; Tomiya T; Mochida S
    PLoS One; 2020; 15(4):e0231427. PubMed ID: 32275701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma.
    Rapposelli IG; Shimose S; Kumada T; Okamura S; Hiraoka A; Di Costanzo GG; Marra F; Tamburini E; Forgione A; Foschi FG; Silletta M; Lonardi S; Masi G; Scartozzi M; Nakano M; Shibata H; Kawata K; Pellino A; Vivaldi C; Lai E; Takata A; Tajiri K; Toyoda H; Tortora R; Campani C; Viola MG; Piscaglia F; Conti F; Fulgenzi CAM; Frassineti GL; Rizzato MD; Salani F; Astara G; Torimura T; Atsukawa M; Tada T; Burgio V; Rimini M; Cascinu S; Casadei-Gardini A
    ESMO Open; 2021 Aug; 6(4):100190. PubMed ID: 34144271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
    Hiraoka A; Kumada T; Kudo M; Hirooka M; Koizumi Y; Hiasa Y; Tajiri K; Toyoda H; Tada T; Ochi H; Joko K; Shimada N; Deguchi A; Ishikawa T; Imai M; Tsuji K; Michitaka K;
    Dig Dis; 2017; 35(6):602-610. PubMed ID: 29040999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade).
    Kariyama K; Hiraoka A; Kumada T; Yasuda S; Toyoda H; Tsuji K; Hatanaka T; Kakizaki S; Naganuma A; Tada T; Takaguchi K; Itobayashi E; Ishikawa T; Shimada N; Tsutsui A; Nagano T; Imai M; Nakamura S; Wakuta A; Miyake N; Shiota S; Nouso K
    J Gastroenterol; 2022 Aug; 57(8):581-586. PubMed ID: 35763116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study.
    Shimose S; Kawaguchi T; Iwamoto H; Tanaka M; Miyazaki K; Ono M; Niizeki T; Shirono T; Okamura S; Nakano M; Suga H; Yamaguchi T; Yokokura Y; Noguchi K; Koga H; Torimura T
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32295043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study.
    Hatanaka T; Naganuma A; Shibasaki M; Kohga T; Arai Y; Nagashima T; Ueno T; Namikawa M; Saito S; Hoshino T; Takizawa D; Arai H; Makita F; Kakizaki S; Harimoto N; Shirabe K; Uraoka T
    Oncology; 2021; 99(4):203-214. PubMed ID: 33279908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation.
    Oh IS; Sinn DH; Kang TW; Lee MW; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Dig Dis Sci; 2017 Nov; 62(11):3235-3242. PubMed ID: 28983724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
    Kikugawa C; Uchikawa S; Kawaoka T; Kinami T; Yano S; Amioka K; Naruto K; Ando Y; Yamaoka K; Tsuge M; Kosaka Y; Ohya K; Mori N; Takaki S; Tsuji K; Kouno H; Kohno H; Morio K; Moriya T; Nonaka M; Aisaka Y; Masaki K; Honda Y; Naeshiro N; Hiramatsu A; Aikata H; Oka S
    Oncology; 2024; 102(3):239-251. PubMed ID: 37729889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma.
    Narita R; Kotoh K; Yoneda A; Motomura M; Harada M
    Anticancer Res; 2020 Sep; 40(9):5271-5276. PubMed ID: 32878816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
    Ando Y; Kawaoka T; Suehiro Y; Yamaoka K; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Azakami T; Takahashi S; Imamura M; Chayama K; Aikata H
    Oncology; 2020; 98(11):787-797. PubMed ID: 32882687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Roles of Ramucirumab in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Koizumi A; Komatsu S; Omiya S; Yano Y; Fujishima Y; Ishida J; Kido M; Gon H; Fukushima K; Urade T; So S; Yoshida T; Arai K; Fujinaka R; Shimura Y; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2024 May; 44(5):2055-2061. PubMed ID: 38677746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study.
    Lee SK; Song MJ; Kim SH; Park M
    PLoS One; 2019; 14(5):e0216173. PubMed ID: 31048923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma.
    Hiraoka A; Kumada T; Michitaka K; Toyoda H; Tada T; Ueki H; Kaneto M; Aibiki T; Okudaira T; Kawakami T; Kawamura T; Yamago H; Suga Y; Miyamoto Y; Tomida H; Azemoto N; Mori K; Miyata H; Ninomiya T; Kawasaki H
    J Gastroenterol Hepatol; 2016 May; 31(5):1031-6. PubMed ID: 26647219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.